- Home
- GAME vs CNTX Comparison
GAME vs CNTX Comparison
Compare GAME & CNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GAME
- CNTX
- Stock Information
- Founded
- GAME 2011
- CNTX 2015
- Country
- GAME United States
- CNTX United States
- Employees
- GAME N/A
- CNTX N/A
- Industry
- GAME
- CNTX Biotechnology: Pharmaceutical Preparations
- Sector
- GAME
- CNTX Health Care
- Exchange
- GAME Nasdaq
- CNTX Nasdaq
- Market Cap
- GAME 70.2M
- CNTX 75.6M
- IPO Year
- GAME 2009
- CNTX 2021
- Fundamental
- Price
- GAME $0.74
- CNTX $0.88
- Analyst Decision
- GAME Strong Buy
- CNTX Strong Buy
- Analyst Count
- GAME 2
- CNTX 5
- Target Price
- GAME $3.00
- CNTX $5.25
- AVG Volume (30 Days)
- GAME 2.6M
- CNTX 86.7K
- Earning Date
- GAME 11-13-2025
- CNTX 11-05-2025
- Dividend Yield
- GAME N/A
- CNTX N/A
- EPS Growth
- GAME N/A
- CNTX N/A
- EPS
- GAME N/A
- CNTX N/A
- Revenue
- GAME $93,375,339.00
- CNTX N/A
- Revenue This Year
- GAME $2.32
- CNTX N/A
- Revenue Next Year
- GAME $26.42
- CNTX N/A
- P/E Ratio
- GAME N/A
- CNTX N/A
- Revenue Growth
- GAME 54.19
- CNTX N/A
- 52 Week Low
- GAME $0.50
- CNTX $0.49
- 52 Week High
- GAME $2.87
- CNTX $2.59
- Technical
- Relative Strength Index (RSI)
- GAME 43.40
- CNTX 60.55
- Support Level
- GAME $0.70
- CNTX $0.81
- Resistance Level
- GAME $0.76
- CNTX $0.87
- Average True Range (ATR)
- GAME 0.05
- CNTX 0.04
- MACD
- GAME 0.01
- CNTX -0.00
- Stochastic Oscillator
- GAME 49.52
- CNTX 74.71
About GAME GameSquare Holdings Inc.
GameSquare Holdings Inc is engaged in revolutionizing the way brands and game publishers connect with hard-to-reach Gen Z, Gen Alpha, and Millennial audiences. It's next generation media, entertainment, and technology helps creators and maximize their brand partners' return on investment. Its purpose-built platform provides marketing and creative services, offers data and analytics solutions, and amplifies awareness through FaZe Clan.
About CNTX Context Therapeutics Inc.
Context Therapeutics Inc is a clinical-stage biopharmaceutical company advancing medicines for solid tumors. The development team is advancing a pipeline of various therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer. The company's preclinical program, CTIM-76, is an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody (bsAb) that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.